PD-1 Inhibitor Active in Rare Cancers

]]>(MedPage Today) -- Almost 30% of patients with advanced rare cancers had no disease progression for more than 6 months when treated with the immune checkpoint inhibitor pembrolizumab (Keytruda), a phase II study found.Results showed that 29 of...